Nachrichten und Videos - AVROBIO INC.

CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation and webcast scheduled for Wednesday, February 6, 2019, at which time the Company will provide clinical trial updates related to its investigational gene therapy program for AVR-RD-01 in Fabry disease. The Company’s presentation and webcast is now scheduled to start at 5:30...

CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis , AVR-RD-04, is cleared to begin a Phase 1/2 clinical trial, following acceptance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). The Phase 1/2 clinical trial is a planned investigator-sponsored trial to be conducted by...

CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related to the Company’s gene therapy program for AVR-RD-01 in Fabry disease will be presented at WORLD Symposium , an annual conference dedicated to lysosomal diseases, being held February 4-8, 2019 in Orlando, Florida. AVROBIO will host an event for analysts and investors in conjunction with the...

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D., to its Board of Directors. Dr. Vickers brings a wealth of global pharmaceutical and biotechnology expertise to AVROBIO, with more than 25 years’ experience in the development and approval of innovative biologics and small molecules to treat diseases in a wide range of therapeutic areas. The...

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). AVROBIO’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market®...

CAMBRIDGE, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-01, for the treatment of Fabry disease. The gene therapy consists of the patient’s own hematopoietic stem cells...

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock options to purchase 293,000 shares of common stock, effective on December 17, 2018. Such options were previously approved by the Compensation Committee, as a material inducement to the employment of Dr. Birgitte Volck, M.D., Ph.D., the Company’s new President of Research and Development. The equity...

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the appointment of four key senior management hires to expand and strengthen its leadership team as it prepares for the next stage of growth. All four leaders will be in place in January 2019 and sit on AVROBIO’s executive leadership team. Three of them, Birgitte Volck, M.D., Ph.D., President of Research and Development, Erik...

During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today reported financial results for the third quarter 2018 and provided a business update. “The third quarter has been...

CAMBRIDGE, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan's 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018. Event: Chardan's 2nd Annual Genetic Medicines Conference Date: Tuesday, October 9, 2018 Time: 3:45 p.m. ET...

Company plans to initiate Phase 1/2 clinical trial in patients with Gaucher disease in 2019 AVROBIO continues to advance its pipeline of gene therapies for lysosomal storage disorders CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (Nasdaq: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that it has received no objection to its clinical trial application...

First two patients in Phase 1 study continue to demonstrate AGA enzyme activity above the diagnostic range for classic Fabry disease 18 months and six months after receiving AVR-RD-01, respectively; Patient 1 is no longer receiving enzyme replacement therapy Enrollment continues in Phase 2 clinical trial and first patient’s 3-month results demonstrate AGA enzyme activity from AVR-RD-01 gene therapy in ERT-naïve patient Company to host a conference call to discuss these additional data today,...